Pediatric Low-Grade Glioma (pLGG) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

According to a literature survey, The annual incidence of pediatric LGGs is 1.5 to 2.35 per 100,000 in the US, estimated to be ~1,550 to 1,950 new diagnoses in 2019. Adult LGG is more common and is estimated to occur at a rate of 9.5 to 13.2 cases per 100,000 individuals in the US, and accounted for ~5,750 new diagnoses in 2019

Read more:- Pediatric Low-Grade Glioma (pLGG) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Low-grade-glioma-forecast

Comprehensive insight on patient segmentation based on age, sex, Histopathologic Subtypes (Grade I & II), subtypes (Glial Tumors; PA, SGCA, DA, PX, OG, Mixed Glioneuronal Tumors; Ganglioglioma, DI-AG, DNT, PGT, RGT, AG, PLNTY, MVNT), Biomarkers (KIAA1549–BRAF, BRAF, NF1, FGFR1/2, RTK, MAPK, ALK/ROS1/NTRK, MEK & Others), Location (CH, Optic-pathway, Brain stream, Spine, ED, Cerebellum), Signs & Symptoms, Clinical Manifestations, Treatment types (Surgery; GTR, NO GTR, Chemotherapy, Radiation therapy & other investigational therapy) has been provided into the epidemiology section of the pLGG and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

CI IMAGE

In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Day One Biopharmaceuticals, Inc., Hoffmann-La Roche, Novartis Pharmaceuticals, Agios Pharmaceuti-cals, Inc., Celldex Therapeutics, Millennium Pharmaceuticals, Inc., Janssen Pharmaceuticals, BeiGene USA, Inc., Daiichi Sankyo Co., Ltd., Boehringer Ingelheim who are targeting the Pediatric Low-grade gliomas (pLGG) market.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Urothelial carcinoma or Transitional cell carcinoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Short bowel syndrome (SBS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Human immunodeficiency virus (HIV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Secondary progressive multiple sclerosis (SMPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Hepatorenal syndrome (HRS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Pediatric Low-Grade Glioma (pLGG), Pediatric Low-Grade Glioma (pLGG) market outlook report, Pediatric Low-Grade Glioma (pLGG) competitive landscape, Pediatric Low-Grade Glioma (pLGG) market forecast